Primary liver cancer, 95% of which is hepatocellular carcinoma (HCC), is ranked third in men and fi fth in women as a cause of death from malignant neoplasms in Japan. The number of deaths and death rate of HCC began to increase sharply in 1975. These numbers peaked at 34 510 and 27.4/100 000, respectively, in 2004, but decreased to 33 662 annual deaths and a 26.7/100 000 death rate in 2006. Although hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are both major causes of HCC, HCV-related HCC represents 70% of all cases. The incidence of HCC without hepatitis B surface antigen (HBsAg) or antibodies to HCV (anti-HCV) accounts for 8%-15% of HCC patients nationwide. Geographically, HCC is more frequent in western than eastern Japan, and death rates of HCC in each prefecture correlate with anti-HCV, but not HBsAg, prevalence. Interferon therapy for chronic hepatitis C reduces the risk of development of HCC, especially among patients with sustained virological response. Further research should focus on the mechanisms of carcinogenesis by HCV and HBV, development of more effective treatments, and establishment of early detection and preventative approaches. Better understanding of HCC unrelated to HCV and HBV, possibly caused by steatohepatitis and diabetes, should also be a major concern in future studies.
Introduction
The three leading causes of death in Japan since 1981 are malignant neoplasms, cardiovascular diseases, and cerebrovascular diseases. For the past 30 years, liver cancer has been the third leading cause of death from malignant neoplasms in men, following lung and stomach cancer. In women, liver cancer has ranked fi fth as a cause of death during the past decade, following colon, stomach, lung, and breast cancer. Primary liver cancer can be classifi ed into three types according to the cell from which the cancer originated, namely, hepatocellular carcinoma (HCC), cholangiocellular carcinoma, and other. As HCC accounts for up 95% of all primary cancer cases, the term "liver cancer" usually means HCC. 1 Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the two major causes of HCC in Japan.
2, 3 The increase in incidence of HCC in Japan, however, is largely attributable to the increase of HCV infection in the general population during the past 50 to 60 years. 
Changes in deaths and death rates of primary liver cancer
Changes in annual deaths from primary liver cancer among different age groups between 1958 and 2006 are shown in Fig. 1 . The total number of deaths from HCC was stable at fewer than 10 000 persons/year until 1975 before showing a sharp increase. The spike in 1995 resulted from a change in the International Classifi cation of Disease (ICD) code from ICD 9 to ICD 10, which included intrahepatic bile duct cancer, accounting for approximately 5% of HCC deaths.
The majority of HCC mortalities were in patients below the age of 69 until 1999, when this age reached 70 years. The death rates of liver cancer by sex (Fig. 2 ) are consistently higher in men than in women. A sharp rise in the death rate of primary liver cancer in men began in 1975, and a more gradual rise in women commenced in 1980. The total age-adjusted death rate peaked in 2002 (27.5/100 000 persons in 2002), and decreased to 27.0 in 2003. In 2006, the total age-adjusted death rate stood at 26.7/100 000, which is caused by a decrease in death rate (36.7) in men, but offset by an increase in women to 17.2.
Age and sex in HCC
Changes in the mean age of HCC patients and male/ female ratio every 2 years between 1984 and 2003 are shown in Fig. 3 . In that period, the mean age of female HCC patients was higher than that of males, and the mean ages of both sexes progressively increased. As reported previously, however, HBV-related HCC was stable from 1982 to 2003, implying that this change originated from HCV-related HCC patients. The male/ female ratio was 4.5 in 1984-1985 and 2.5 in 2002-2003 (see Fig. 3 ), showing that the proportion of female patients with HCC had increased. This increase in female patients is also considered as a consequence of increased HCV-related HCC.
Changes in etiology of HCC in Japan
A nationwide survey on primary liver cancer has been conducted every 2 years since 1968 by the Liver Cancer Study Group of Japan. In cross-sectional studies conducted at Shinshu University Hospital, HCV-related HCC was found in the majority of cases (72%) (Fig. 5) . Non-B non-C HCC (NBNC-HCC) accounted for 10% of cases in 2002-2007. In these 28 patients, nonalcoholic steatohepatitis (NASH) accounted for 14%.
Geographic variation of liver cancer and HBV/HCV infection
Although Japan is a relatively small country with a homogeneous population, the incidence of HCC varies greatly among different regions. The Vital Statistics of Japan for 2005 published in 2007 by the Japanese Ministry of Health, Labour, and Welfare on the incidence of deaths as a result of HCC in its 48 prefectures shows a steady increase in death rates of HCC from east to west in Japan. The average age-adjusted death rate of HCC among 48 prefectures was 27.2 per 100 000 persons in 2005 (Fig. 6) . Furthermore, nationwide health screening for HBsAg and anti-HCV in citizens over 40 years of age has been performed since 2002, and the prevalence rates of these markers have been analyzed for each prefecture in Japan. In 2006, the average HBsAg and anti-HCV prevalences were 1.0% and 0.7%, respectively, in this group (see Fig. 6 ). There was a highly signifi cant association between the death rate of HCC and prevalence of anti-HCV in each prefecture ( Fig. 7 ; correlation coeffi cient = 0.66; P < 0.001, (Fig. 6 ). For instance, although Okinawa Prefecture had the highest prevalence of HBsAg (2.6%), its HCC death rate was the lowest (12.5/100 000 persons). A possible explanation for this discrepancy is that the HBV genotype Bj, which shows good clinical prognosis, 10, 11 is the dominant HBV genotype in Okinawa. In contrast, areas with high rates of anti-HCV, especially in western Japan, had high death rates from HCC. HCV appears to be the major contributor to primary liver cancer in these regions; Saga Prefecture shows both the highest HCC death rate (46.9/100 000) and highest prevalence rate of anti-HCV (2.1%) in Japan.
Antiviral therapy suppresses the incidence of HCC
As described in prior sections, HCV infection is the major cause of HCC in Japan, suggesting that eradication of HCV may decrease the incidence of HCC. A summary of different studies on the incidence of HCC among patients with chronic hepatitis C who were treated with interferon in Japan can be found in Table  1 . [12] [13] [14] [15] [16] [17] These studies show a moderate decrease in the risk of HCC in patients with chronic hepatitis C treated with interferon, especially in patients with sustained virological response as compared with nonresponders and nontreated patients.
Recently, Ikeda et al. prospectively studied patients with chronic HCV infection and evidence of occult HBV infection [negative results for HBsAg and HBV DNA but positive results for antibodies to hepatitis B core antigen (anti-HBc) in serological testing]. 17 Patients with HCV-related cirrhosis and positive results for antiHBc were at high risk for HCC, even in patients with a sustained virological response to interferon (IFN) therapy. Thus, anti-HBc positivity is a marker of high risk for HCC among patients with HCV-related cirrhosis.
Between 1992 and 2001, approximately 300 000 patients with chronic hepatitis C received IFN monotherapy in Japan. As shown in Fig. 1 , it is remarkable that the number of deaths and the death rate of HCC began to decrease in 2005. These phenomena suggest that antiviral treatment indeed reduces the risk of HCC in patients with HCV infection.
Conclusion
The number of deaths and death rate of HCC showed a sharp increase from 1975 onward but had begun to decrease in 2006. Although both HBV and HCV infection play a major role in HCC in Japan, HCV-related HCC represents 70% of all cases. The incidence of HCC without HBsAg or anti-HCV accounts for 7%-15% in Japan, and half of NBNC-HCC cases are of unknown origin. Geographically, HCC is more frequent in western than eastern Japan, and the death rates of HCC in each prefecture correlate with anti-HCV, but not HBsAg, prevalence. IFN therapy for chronic hepatitis C reduces the risk of development of HCC, especially in patients with sustained viral response. Table 1 . Summary of fi ndings in representative studies on the incidence of hepatocellular carcinoma (HCC) among patients with chronic hepatitis C virus (HCV) infection treated with interferon alone in Japan
